Core Insights - Health Catalyst, Inc. has been recognized as a leader in innovation in the Frost Radar™: US Population Health Management, 2024 report, solidifying its position in the competitive population health management market [1][2][3] Company Overview - Health Catalyst provides data and analytics technology and services to healthcare organizations, focusing on enhancing care delivery and outcomes through its Population Health suite, which includes financial and quality benchmarking tools, administrative support, and advanced analytics [2][3] - The company has a multi-decade mission dedicated to equipping healthcare organizations with tools for data-informed healthcare improvement and operational efficiency [3][6] Innovation and Growth - The report highlights Health Catalyst's optimization efforts, including custom configuration, a pre-built rules engine, and superior data management capabilities, which contribute to the success of population health management initiatives [3][4] - Health Catalyst's proactive approach to innovation is underscored by its strategic acquisitions, such as Carevive and Lumeon, which enhance its capabilities in oncology care management and patient communication [3][5] Market Position - Analysts commend Health Catalyst's balanced focus on growth and innovation, which positions the company well to meet the needs of clients of all sizes [4][5] - The company's strategic expansion into underserved segments, including ambulatory practices and smaller healthcare organizations, further solidifies its leadership in the population health management market [5]

Investment Thesis - The company, Health Catalyst (NASDAQ: HCAT), is recommended as a buy due to expected growth acceleration driven by an improved macro environment and traction with the Ignite platform [1] - The investment is considered ideal if the company operates in a sector projected to experience structural (organic) growth exceeding GDP growth over the next 5-10 years [1] - The company should profit from sustainable competitive advantages that translate into attractive unit economics [1] - The company should be managed by competent, ethical, and long-term thinkers [1] - The company should have a fair valuation [1] Analyst's Position - The analyst has no stock, option, or similar derivative position in any of the companies mentioned and no plans to initiate any such positions within the next 72 hours [1] - The article expresses the analyst's own opinions and is not receiving compensation for it (other than from Seeking Alpha) [1] - The analyst has no business relationship with any company whose stock is mentioned in the article [1]

SALT LAKE CITY, Nov. 20, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"  Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of an AI-powered version of BluePrint Protect™ from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties.On Nov. 6, Health Catalyst announced it signed a defini ...

SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the Stephens Annual Investment Conference, being held in Nashville, including a fireside chat on Wedne ...

Health Catalyst (HCAT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30%. A quarter ago, it was expected that this provider of data analytics for the health care industry would post earnings of $0.09 per share when it actually produced earnings of $0.12, delivering a surprise of 33 ...

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Intraprise Health, LLC ("Intraprise"), a tech-enabled cybersecurity provider offering an end-to-end cybersecurity risk management platform and services to protect its clients from cyberattacks and manage follow-on liability in the event of an incident. ...

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jill Hoggard Green, RN, BSN, MS, PhD, FAAN, former Chief Executive Officer of The Queen's Health Systems, has been appointed to serve as a member of Health Catalyst's board of directors ("Board") and a member of its Compensation Committee, effective December 1, 2024."Jill has been an extraordina ...

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst,"Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a new partnership with CyncHealth, the designated statewide health information exchange (HIE) for Iowa.This partnership will enhance CyncHealth's ability to provide comprehensive and timely patient health information to healthcare providers. CyncHealth will improve the quality of care within its netw ...

SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2024. “For the third quarter of 2024, I am pleased with our strong financial results, including total revenue of $76.4 million and Adjusted EBITDA of $7.3 million, with these results exceeding the mid-point of our quarterly guidance on each m ...

Core Viewpoint - Health Catalyst (HCAT) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance and Outlook - The recent upgrade for Health Catalyst indicates a positive outlook for its earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - Health Catalyst is projected to earn $0.36 per share for the fiscal year ending December 2024, reflecting a year-over-year increase of 140% [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7]. - Health Catalyst's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].